No Prescription |
 |
 | ||
|
LAMVIR 3TC |
|
| ||
No Prescription » Prescription Drugs 9 » LAMVIR 3TC Lamivudine is used in combination with other medications to treat human immunodeficiency virus (HIV) infection in patients with acquired immunodeficiency syndrome (AIDS). Lamivudine is not a cure and may not decrease the number of HIV-related illnesses. Lamivudine does not prevent the spread of HIV to other people. Lamivudine is used to treat hepatitis B infection. Lamivudine is in a class of medications called nucleoside reverse transcriptase inhibitors. It works by stopping the spread of the HIV and hepatitis B viruses.Lamivudine comes as a tablet and liquid to take by mouth. Lamivudine (Epivir) is usually taken every 12 hours (twice a day). Lamivudine (Epivir-HBV) is usually taken once a day. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take lamivudine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.Continue to take lamivudine even if you feel well. Do not stop taking lamivudine without talking to your doctor.Lamivudine is also used sometimes in combination with zidovudine (Retrovir AZT) to treat health-care workers or other individuals exposed to HIV infection after accidental contact with HIV-contaminated blood tissues or other body fluids. Talk to your doctor about the possible risks of using this drug for your condition. Buy LAMVIR 3TC and other Prescription Drugs 9 products online at Medstore. 506
About LAMVIR 3TC: Product Type: Prescription Drugs 9 LAMVIR ( 3TC Epivir Epivir-HBV Generic Lamivudine ) LAMVIR (3TC Epivir Epivir-HBV Generic Lamivudine) 3TC Epivir Epivir-HBV Generic Lamivudine 150mg Tabs 30 (3 x 10) 3TC Epivir Epivir-HBV Generic Lamivudine LAMVIR
View more Prescription Drugs 9 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
